1. Home
  2. NTRSO vs SCLXW Comparison

NTRSO vs SCLXW Comparison

Compare NTRSO & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northern Trust Corporation

NTRSO

Northern Trust Corporation

N/A

Current Price

$19.24

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

N/A

Current Price

$0.17

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NTRSO
SCLXW
Founded
N/A
N/A
Country
United States
United States
Employees
23300
31
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NTRSO
SCLXW
Price
$19.24
$0.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
N/A
4.0K
Earning Date
N/A
03-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$55,152,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.02
52 Week Low
N/A
$0.18
52 Week High
N/A
$0.18

Technical Indicators

Market Signals
Indicator
NTRSO
SCLXW
Relative Strength Index (RSI) 34.63 42.90
Support Level $19.37 $0.17
Resistance Level $19.71 $0.21
Average True Range (ATR) 0.17 0.03
MACD -0.01 -0.00
Stochastic Oscillator 6.00 47.62

Price Performance

Historical Comparison
NTRSO
SCLXW

About NTRSO Northern Trust Corporation

Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of December 2024, Northern Trust had assets under custody or administration of $16.8 trillion and assets under management of $1.6 trillion.

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: